Description: STE is buoyed by strong Healthcare and AST growth, solid margins and balance sheet strength, even as macro pressures and competition loom.

Description: TEM shares are up 82.4% in a year as Genomics revenues surge, Data & Services scale, FDA clearances and EBITDA turns positive.

Description: Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, today announced that it will report fourth quarter and full year 2025 financial results on Tuesday, February 10, 2026, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day.

Description: BSX is seeing solid international growth, MedSurg market-share gains and surging WATCHMAN sales, though macro and competition remain risks.

Description: RMD is seeing rising device demand, expanding international sales and strong liquidity, but macroeconomic pressures could weigh on future performance.

Description: If you are wondering whether Quest Diagnostics shares still offer good value at around US$178.14, the key question is how that price compares with what the business might reasonably be worth. The stock has returned 2.7% over the last week and 2.5% year to date, with a 17.8% return over the past year and 56.6% over five years. These figures may affect how you think about potential upside or downside from here. Recent attention on Quest Diagnostics has centered on its role as a major medical...

Description: Envista's global expansion, bolt-on acquisitions, and strong balance sheet support growth, even as currency swings pressure sales.

Description: IDXX shares surge 64.7% in a year as CAG Diagnostics momentum, strong retention and expanding software adoption fuel growth across regions.

Description: SAN DIEGO, January 06, 2026--PracticeQ and Fullscript partner to simplify lab ordering and results management, helping providers deliver faster, more connected care.

Description: Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that data will be shared on circulating tumor DNA (ctDNA) minimal residual disease (MRD) testing during two poster presentations at the 2026 ASCO Gastrointestinal Cancers Symposium, being held January 8-10, 2026 in San Francisco, CA., and online. The studies evaluate the use of ctDNA in colorectal cancer using the Haystack MRD® test from Quest Diagnostics.

Description: HOLX's Breast Health unit is back in focus as a proposed Blackstone-TPG deal adds a $76 cash offer and CVR to 2026-27 revenue goals.

Description: LH's growth bets in specialty testing and acquisitions support its outlook, but macro pressures and currency headwinds remain key risks.

Description: Quest Diagnostics (DGX) has been drawing attention after recent trading left the shares with a negative move over the past month and past 3 months, prompting investors to reassess the company’s fundamentals and valuation. See our latest analysis for Quest Diagnostics. At a share price of US$173.49, Quest Diagnostics has seen short term share price pressure, with a 30 day share price return of 4.94% and a 90 day share price return of 4.09%. This comes even as its 1 year total shareholder...

Description: Corewell Health and Quest Diagnostics (NYSE: DGX) today announced the completion of the previously announced transaction to establish a laboratory services joint venture to expand access to innovative, quality and affordable laboratory services in Michigan.

Description: Quest Diagnostics is expected to unveil its fourth-quarter results soon, and analysts expect a single-digit growth in earnings.

Description: PODD gains momentum as Omnipod 5 adoption accelerates, margins scale, and earnings estimates rise despite macro and concentration risks.

Description: Quest Diagnostics (DGX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Description: DGX banks on acquisitions, advanced diagnostics and cost discipline, even as debt levels and macro pressures pose risks.

Description: Here is how Quest Diagnostics (DGX) and Elicio Therapeutics (ELTX) have performed compared to their sector so far this year.

Description: Quest Diagnostics Incorporated (NYSE: DGX), a leading national provider of diagnostic information services, announced that Jim Davis, Chairman, CEO and President, and Sam Samad, Executive Vice President and Chief Financial Officer, will speak on the company's strategy, performance, and the latest market developments and trends during a presentation and Q&A session at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 12, 2026, at 4:30 p.m. Pacific Time.

Description: Quest Diagnostics (NYSE:DGX) has had a rough month with its share price down 5.3%. But if you pay close attention, you...

Description: Quest Diagnostics has outperformed the broader healthcare sector over the past year. Moreover, Wall Street analysts remain moderately optimistic about its prospects.

Description: In recent weeks, Oracle announced it unanimously elected former Quest Diagnostics CEO Stephen Rusckowski to its board, while Orca Security revealed its Cloud Native Application Protection Platform is now available in Oracle Cloud Marketplace for deployment on Oracle Cloud Infrastructure. This period also saw market and analyst focus shift toward Oracle's substantial increase in debt to fund AI data center expansion, prompting debate over its financial risk and reliance on large-scale OpenAI...

Description: MENLO PARK, Calif., December 01, 2025--Octave Bioscience, a commercial-stage precision care company pioneering a new standard for managing multiple sclerosis (MS) and other neurodegenerative diseases such as Parkinson’s disease, today announced a strategic collaboration with Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, to make the OctaveⓇ Multiple Sclerosis Disease Activity (MSDA) Test accessible through Quest’s nationwide specimen-collection network.

Description: Ever wondered if Quest Diagnostics stock is actually a bargain right now, or just riding the latest market waves? You are in the right place to get some clarity. The stock has made an impressive move, jumping 8.2% over the past month and delivering a strong 25.3% gain year-to-date. There is clear momentum, which may indicate renewed optimism or shifting risk perception. In recent weeks, Quest Diagnostics has been in the spotlight due to fresh partnerships and positive...

Description: DaVita HealthCare (DVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Description: Chemed (CHE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Description: DGX's strong YTD gains and momentum in advanced diagnostics and acquisitions highlight why it may stand out in the competitive testing market against HOLX.

Description: DGX pushes growth through acquisitions and advanced diagnostics even as rising debt and tough competition pressure its outlook.

Description: A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut.

Description: Quest Diagnostics posted higher third-quarter earnings and revenue, both topping market expectations and showing clear improvement from last year. The company also raised its full-year revenue outlook, which signals sustained business momentum. See our latest analysis for Quest Diagnostics. Quest Diagnostics’ robust third-quarter results have combined with a solid run for shareholders this year, as the stock’s year-to-date price return sits at an impressive 24.28%. With a recently affirmed...

Description: Oracle Corporation (NYSE: ORCL) today announced that it unanimously elected Stephen Rusckowski to Oracle's Board of Directors and increased the size of the Board to 14. The election is effective as of November 18, 2025.

Description: Quest Diagnostics (DGX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Description: Quest Diagnostics has outperformed the broader market over the past year, and analysts are moderately optimistic about the stock’s prospects.

Description: TEM hits its first positive adjusted EBITDA as strong Genomics and Data Licensing growth pairs with tighter cost discipline.

Description: Quest Diagnostics' fair value estimate remains steady at $197.25 per share, with only a slight uptick in the discount rate. This reflects minimal change in the firm's valuation assessment. While the company continues to project steady revenue growth, recent analyst sentiment highlights both enthusiasm and caution following strong quarterly results and an impressive guidance update. Stay tuned to discover how evolving analyst views and company performance can help you navigate future updates...

Description: The takeover extends a string of deals that have consolidated the outreach lab services market.

Description: The telehealth platform expects the new offering to add to its user base as it draws customers looking to prevent future health issues.

Description: Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.80 per share, payable on January 28, 2026 to shareholders of record of Quest Diagnostics common stock on January 13, 2026.

Description: Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Sam Samad, Executive Vice President and Chief Financial Officer, will speak on the company's strategy, performance and the latest market developments and trends during Citi's 2025 Global Healthcare Conference in Miami on Tuesday, December 2, 2025, at 3:15 p.m. Eastern Time.

Description: Quest Diagnostics (DGX) stock climbed slightly today, gaining just above 0% after a relatively quiet session. Investors seem to be weighing recent performance, as shares are up 17% year-to-date and have outperformed over the past year. See our latest analysis for Quest Diagnostics. Quest Diagnostics has kept a steady pace in 2024, with a year-to-date share price return of 16.55% building on persistent gains seen over the past year. Notably, the company’s 1-year total shareholder return of...

Description: Quest Diagnostics has seen its Fair Value Estimate rise moderately from $191.56 to $197.25 per share, reflecting a more optimistic outlook among analysts. This upward revision is largely due to strong quarterly results and an overall positive sentiment from Wall Street. Stay tuned to learn how you can track future changes in the stock's narrative as new developments unfold. Stay updated as the Fair Value for Quest Diagnostics shifts by adding it to your watchlist or portfolio. Alternatively,...

Description: Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.

Description: Personal health and wellness is one of the many secular tailwinds for healthcare companies. But speed bumps such as inventory destockings have persisted in the wake of COVID-19, limiting growth. This has capped returns as the industry’s six-month gain of 9.8% has lagged the S&P 500’s 22.6% climb.

Description: The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Description: Two blood tests, each involving multiple biomarkers, are highly accurate at identifying Alzheimer's disease pathology in symptomatic patients, supporting diagnosis, according to a new study in Neurology® Clinical Practice, a publication of the American Academy of Neurology.

Description: Earlier this week, Quest Diagnostics reported third-quarter earnings exceeding expectations, raised its full-year guidance, and expanded its partnership and acquisition activity to further grow its diagnostic services business. Notably, Quest’s results were supported by strong year-over-year revenue and net income growth, reflecting rising demand, operational efficiency, and investments in technology and partnerships that aim to broaden its offering and reach. We’ll examine how the raised...

Description: Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.

Description: We came across a bullish thesis on Quest Diagnostics Incorporated on Quality Value Investing’s Substack by David J. Waldron. In this article, we will summarize the bulls’ thesis on DGX. Quest Diagnostics Incorporated’s share was trading at $185.39 as of October 14th. DGX’s trailing and forward P/E were 21.67 and 17.12 respectively according to Yahoo Finance. Quest […]

Description: Quest Diagnostics' (DGX) fundamentals remain strong despite a temporary margin "blip" that weighed o

Description: Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Description: Quest Diagnostics (DGX) delivered a 15.4% earnings growth over the past year, beating its five-year average where earnings had declined by 18.5% per year. Analysts are calling for continued but slower EPS growth at 8.9% per year and revenue increases of 3.4% annually. Both rates trail the broader US market’s growth rates. Margins have edged higher, with the company posting a net profit margin of 8.9%, a slight uptick from last year’s 8.8%, reflecting gradual improvements in near-term...

Description: Quest Diagnostics Inc (DGX) reports a 13.1% revenue increase and raises full-year guidance, driven by robust demand and strategic initiatives.

Description: Opportunities in the global fertility test market include rising demand due to lifestyle changes, delayed pregnancies, and increasing infertility rates. Growing awareness and acceptance of fertility testing, alongside the prevalence of reproductive disorders, also drive market expansion across diverse demographics globally. Fertility Test Market Fertility Test Market Dublin, Oct. 21, 2025 (GLOBE NEWSWIRE) -- The "Fertility Test Market Size, Share & Trends Analysis Report by Test Type (Ovulation

Description: DGX posts a strong Q3 with revenues and EPS beating estimates, higher margins and an upbeat full-year outlook.

Description: The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.04% and the actively tra

Description: Quest Diagnostics (DGX) delivered earnings and revenue surprises of +3.59% and +3.45%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Description: Healthcare diagnostics company Quest Diagnostics (NYSE:DGX) reported revenue ahead of Wall Street’s expectations in Q3 CY2025, with sales up 13.2% year on year to $2.82 billion. The company’s full-year revenue guidance of $10.98 billion at the midpoint came in 1% above analysts’ estimates. Its non-GAAP profit of $2.60 per share was 3.9% above analysts’ consensus estimates.

Description: SECAUCUS, N.J. (AP) — Quest Diagnostics Inc. DGX) on Tuesday reported third-quarter profit of $245 million. The Secaucus, New Jersey-based company said it had profit of $2.16 per share.

Description: Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, today announced financial results for the third quarter ended September 30, 2025.

Description: Healthcare diagnostics company Quest Diagnostics (NYSE:DGX) will be reporting earnings this Tuesday before market hours. Here’s what you need to know.

Description: Quest Diagnostics has seen its Fair Value Estimate rise slightly, climbing from $188.19 to $191.56 per share as analysts factor in updated growth expectations. This change is supported by increased revenue growth projections, reflecting renewed optimism in the company's outlook following recent research and 2025 guidance updates. Stay tuned to discover how investors can monitor ongoing updates and shifts in Quest's evolving narrative. What Wall Street Has Been Saying Analyst sentiment...

Description: The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.

Description: TEM expands its AI-driven growth with new collaborations in oncology, neurogenomics, and diagnostic innovation.